PASLI Disease - 2 Studies Found
| Completed |
: Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI : Activated PI3Kdelta Syndrome (APDS); PASLI Disease : 2016-08-04 : Drug: CDZ173 140 mg/day |
| Completed |
: Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled GSK2269557 in Patients With APDS/PASLI : Activated PI3K-delta Syndrome : 2015-10-29 : Drug: GSK2269557 DPI 500 mcg Subjects will receive 2 inhalations of GSK2269557 500 mcg in DPI (total dos |